PMC:7652766 / 96704-97045 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"3515","span":{"begin":156,"end":158},"obj":"Gene"},{"id":"3516","span":{"begin":49,"end":51},"obj":"Gene"},{"id":"3517","span":{"begin":3,"end":5},"obj":"Gene"},{"id":"3519","span":{"begin":147,"end":150},"obj":"Gene"},{"id":"3524","span":{"begin":17,"end":29},"obj":"Disease"},{"id":"3525","span":{"begin":59,"end":67},"obj":"Disease"},{"id":"3547","span":{"begin":300,"end":302},"obj":"Gene"},{"id":"3548","span":{"begin":250,"end":258},"obj":"Species"},{"id":"3549","span":{"begin":321,"end":329},"obj":"Species"},{"id":"3552","span":{"begin":187,"end":188},"obj":"Gene"},{"id":"3553","span":{"begin":264,"end":272},"obj":"Disease"},{"id":"3554","span":{"begin":312,"end":320},"obj":"Disease"}],"attributes":[{"id":"A3515","pred":"tao:has_database_id","subj":"3515","obj":"Gene:6999"},{"id":"A3516","pred":"tao:has_database_id","subj":"3516","obj":"Gene:6999"},{"id":"A3517","pred":"tao:has_database_id","subj":"3517","obj":"Gene:6999"},{"id":"A3519","pred":"tao:has_database_id","subj":"3519","obj":"Gene:3439"},{"id":"A3524","pred":"tao:has_database_id","subj":"3524","obj":"MESH:D007249"},{"id":"A3525","pred":"tao:has_database_id","subj":"3525","obj":"MESH:C000657245"},{"id":"A3547","pred":"tao:has_database_id","subj":"3547","obj":"Gene:6999"},{"id":"A3548","pred":"tao:has_database_id","subj":"3548","obj":"Tax:9606"},{"id":"A3549","pred":"tao:has_database_id","subj":"3549","obj":"Tax:9606"},{"id":"A3552","pred":"tao:has_database_id","subj":"3552","obj":"Gene:351"},{"id":"A3553","pred":"tao:has_database_id","subj":"3553","obj":"MESH:C000657245"},{"id":"A3554","pred":"tao:has_database_id","subj":"3554","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"rs to exacerbate inflammation in the progression to severe COVID-19; the timing of administration and subgroups targeted for treatment with type I IFN need to be considered with caution.\nA recent retrospective multicenter cohort study of 446 Chinese patients with COVID-19 reported that among severe to critical COVID-19 patients, early admi"}